Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Trial Details
- NCT ID
- NCT03125642
- Phase
- PHASE2
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Etoposide
- BCNU
- AraC
- Melphalan
- Peripheral blood stem cell transplantation
- G-CSF
- Locations (sample)
- Minneapolis, Minnesota, United States|44.97997,-93.26384
Key Eligibility Criteria
- Eligible Diseases
- Non-Hodgkin's Lymphoma (NHL)
- Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.
- Patients in partial or complete remission following cell therapy will also be eligible.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →